Japan's Generic Market Primed For Growth, But Distribution And Manufacturing Barriers Remain
This article was originally published in PharmAsia News
Substantial patent expirations in the next few years and government incentives for generic use make Japan's generic market ideal for midterm growth, but stringent API standards and complex distribution channels have left some foreign firms in a difficult spot.
You may also be interested in...
MHLW Relied On EU and U.S. For Actos Safety Data, But Newly Funded Health Records Database Will Boost Japan's Pharmacovigilance
The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?
Astellas’ geographic and indication expansion strategy for Xtandi matches patent losses in Japan.